Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.

Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C.

Health Technol Assess. 2003;7(9):v-vi, 1-98. Review. No abstract available.

PMID:
12709292
[PubMed - indexed for MEDLINE]
Free Article
2.

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Ophthalmology. 2007 Jun;114(6):1170-8. Epub 2007 Feb 23.

PMID:
17320964
[PubMed - indexed for MEDLINE]
3.

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

Brown GC, Brown MM, Campanella J, Beauchamp GR.

Am J Ophthalmol. 2005 Oct;140(4):679-87.

PMID:
16226519
[PubMed - indexed for MEDLINE]
4.

Computerized model of cost-utility analysis for treatment of age-related macular degeneration.

Fletcher EC, Lade RJ, Adewoyin T, Chong NV.

Ophthalmology. 2008 Dec;115(12):2192-8. doi: 10.1016/j.ophtha.2008.07.018. Epub 2008 Oct 18.

PMID:
18930556
[PubMed - indexed for MEDLINE]
5.

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.

Bansback N, Davis S, Brazier J.

Eye (Lond). 2007 Dec;21(12):1455-63. Epub 2006 Nov 10.

PMID:
17086167
[PubMed - indexed for MEDLINE]
6.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

PMID:
18513468
[PubMed - indexed for MEDLINE]
Free Article
7.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

PMID:
18462575
[PubMed - indexed for MEDLINE]
Free Article
8.

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.

PMID:
18035208
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51. doi: 10.1016/j.clinthera.2008.12.025.

PMID:
19167602
[PubMed - indexed for MEDLINE]
10.

[Cost-effectiveness of photodynamic therapy in age-related macular degeneration].

Muslera E, Natal C.

Arch Soc Esp Oftalmol. 2006 Apr;81(4):199-204. Spanish.

PMID:
16688643
[PubMed - indexed for MEDLINE]
Free Article
11.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

PMID:
15361313
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.

Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, Chakravathy U, Carpenter J, Reeves BC; Verteporfin Photodynamic Therapy Cohort Study Group.

Ophthalmology. 2009 Dec;116(12):2471-77.e1-2. doi: 10.1016/j.ophtha.2009.10.023.

PMID:
19948278
[PubMed - indexed for MEDLINE]
14.

A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.

Wickens J, Blinder KJ.

Drug Saf. 2006;29(3):189-99. Review.

PMID:
16524319
[PubMed - indexed for MEDLINE]
15.

Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties.

Cruess AF, Zlateva G, Pleil AM, Wirostko B.

Acta Ophthalmol. 2009 Mar;87(2):118-32. doi: 10.1111/j.1755-3768.2008.01218.x. Epub 2008 Jun 13. Review.

PMID:
18577193
[PubMed - indexed for MEDLINE]
16.

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

Brown MM, Brown GC, Brown HC, Peet J.

Ophthalmology. 2008 Jun;115(6):1039-1045.e5. Epub 2007 Nov 5.

PMID:
17976724
[PubMed - indexed for MEDLINE]
17.

The cost-effectiveness of treatment of age-related macular degeneration: a review.

Kymes Steven M.

Minerva Med. 2009 Feb;100(1):69-78. Review.

PMID:
19277005
[PubMed - indexed for MEDLINE]
18.

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].

Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German.

PMID:
17846963
[PubMed - indexed for MEDLINE]
19.

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.

PMID:
17887807
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk